Logo
Contact Us
Banner

Patritumab

Products

Quote Request

Patritumab

Patritumab

Catalog No.: PC0059

Size: 1 mg, 5 mg,10 mg, 25 mg,50 mg, 100 mg

Description

Patritumab (human anti-ERBB3 recombinant antibody) is a neutralizing monoclonal antibody directed against ERBB3. Patritumab acts synergistically with cetuximab (HY-P9905) to effectively inhibit the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces apoptosis and inhibits the growth of pancreatic, non-small cell lung, and colorectal cancer xenograft tumors.

CAS No. 1262787-83-6
Appearance Liquid
Color Colorless to light yellow
Shipping Shipping with dry ice.
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
In Vitro Patritumab targets to the extracellular domain (ECD) of HER3 and (10 μg/mL; 5 d) induces DiFi-HRG4 cells apoptosis.
Patritumab (10 μg/mL; 6 h) markedly inhibits the phosphorylation of HER3 and AKT, without affecting that of ERK, in DiFi-HRG4 cells.
Patritumab (10 μg/mL; 48 h) also induces the cleavage of PARP accompanied with both up-regulation of BIM and down-regulation of survivin expression.
In Vivo Patritumab (1 mg/mouse; i.p.; twice a week for 4 weeks) combines with 1 mg Cetuximab and restores Cetuximab sensitivity in DiFi-HRG tumor xenografts model in mice.
Heregulin produced by colorectal cancer tumors harboring wild-type KRAS induces Cetuximab resistance, and that combination therapy with cetuximab and patritumab overcomes such resistance in vivo.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Logo

As the scientific machine continues to turn, Alfa Cytology is committed to keeping pace. We continue to expand our services and improve our existing resources to help our customers accelerate their research and support their careers.

Company
Our Services
Our Products

Copyright © Alfa Cytology. All rights reserved.